

SUPPLEMENTARY MATERIAL

Additional references for the sections on pathogenesis, biomarkers, treatment and then each table are listed below.

Pathogenesis

Human Gene Mutation Database version 2018.2. www.hgmd.cf.ac.uk (accessed December 2019).

Litwin T, Gromadzka G, Członkowska A. Apolipoprotein E gene (APOE) genotype in Wilson's disease; Impact on clinical presentation. *Parkinsonism Relat Dis.* 2012;18:367-369.

Meenakshi-Sundaram S, Mahadevan A, Taly AB, *et al.* Wilson's disease: a clinico-neuropathological autopsy study. *J Clin Neurosci* 2008;15(4):409-17.

Stern G. Die Pathoklise [Parkinson's disease]. *J Neural Transm Suppl* 1993;40:93-9.

Bruehlmeier M, Leenders KL, Vontobel P, *et al.* Increased cerebral iron uptake in Wilson's disease: a ⁵²Fe-citrate PET study. *J Nucl Med* 2000;41(5):781-7.

Biomarkers

Poujois A, Woimant F. Chapter 10 - Biochemical Markers. In: Weiss KH, Schilsky M, eds. *Wilson Disease*. Academic Press; 2019:115-124.

Trocello JM, El Balkhi S, Woimant F, *et al.* Relative exchangeable copper: a promising tool for family screening in Wilson disease. *Mov Disord* 2014;29(4):558-62.

Guillaud O, Brunet AS, Mallet I, *et al.* Relative exchangeable copper: A valuable tool for the diagnosis of Wilson disease. *Liver Int* 2018;38(2):350-357.

Barbosa ER, Caramelli P, Bacheschi LA, *et al.* Wilson's disease: magnetic resonance imaging (MRI) with clinical correlations in 16 cases. *Rev Paul Med* 1993;111(3):407-11.

Starosta-Rubinstein S, Young AB, Kluin K, *et al.* Clinical assessment of 31 patients with Wilson's disease. Correlations with structural changes on magnetic resonance imaging. *Arch Neurol* 1987;44(4):365-70.

Magalhaes AC, Caramelli P, Menezes JR, *et al.* Wilson's disease: MRI with clinical correlation. *Neuroradiology* 1994;36(2):97-100.

Oder W, Prayer L, Grimm G, *et al.* Wilson's disease: evidence of subgroups derived from clinical findings and brain lesions. *Neurology* 1993;43(1):120-4.
EASL. EASL Clinical Practice Guidelines: Wilson's disease. *J Hepatol* 2012;56(3):671-85.

Ryan A, Nevitt SJ, Tuohy O, *et al.* Biomarkers for diagnosis of Wilson's disease. *Cochrane Database Syst Rev* 2019;2019(11).

Seniów J, Bąk T, Gajda J, *et al.* Cognitive functioning in neurologically symptomatic and asymptomatic forms of Wilson's disease. *Mov Dis* 2002;17(5):1077–1083.

Leśniak M, Członkowska A, Seniów J, Abnormal antisaccades and smooth pursuit eye movements in patients with Wilson' disease. *Mov Dis* 2008;23(14):2067–2073.

Treatments

Członkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson's disease with D-penicillamine and zinc sulphate. *J Neurol* 1996;243(3):269-73.

Weiss KH, Thurik F, Gotthardt DN, *et al.* Efficacy and safety of oral chelators in treatment of patients with Wilson disease. *Clin Gastroenterol Hepatol* 2013;11(8):1028-35 e1-2.

Table 1

Członkowska A, Litwin T, Dziezyc K, *et al.* Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson's Disease Rating Scale. *BMC Neurol* 2018;18(1):34.

Machado A, Chien HF, Deguti MM, *et al.* Neurological manifestations in Wilson's disease: Report of 119 cases. *Mov Disord* 2006;21(12):2192-6.

Walshe JM, Yealland M. Wilson's disease: the problem of delayed diagnosis. *J Neurol Neurosurg Psychiatry* 1992;55(8):692-6.

Dening TR, Berrios GE. Wilson's disease. Psychiatric symptoms in 195 cases. *Arch Gen Psychiatry* 1989;46(12):1126-34.

Svetel M, Potrebic A, Pekmezovic T, *et al.* Neuropsychiatric aspects of treated Wilson's disease. *Parkinsonism Relat Disord* 2009;15(10):772-5.

Zimbrea PC, Schilsky ML. Psychiatric aspects of Wilson disease: a review. *Gen Hosp Psychiatry* 2014;36(1):53-62.

Przybyłkowski A, Gromadzka G, Chabik G, *et al.* Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson's disease. *Funct Neurol* 2014;29(1):23-9.

Table 2

T1-weighted (structural) imaging

Stein A, George L, Jhunjhunwala K, *et al.* Exploring cortical atrophy and its clinical and biochemical correlates in Wilson's disease using voxel based morphometry. *Parkinsonism Relat Disord* 2016;30:52-7.

Smolinski L, Litwin T, Redzia-Ogrodnik B, *et al.* Brain volume is related to neurological impairment and to copper overload in Wilson's disease. *Neurol Sci* 2019;40(10):2089-2095.

Zou L, Song Y, Zhou X, *et al.* Regional morphometric abnormalities and clinical relevance in Wilson's disease. *Mov Disord* 2019;34(4):545-554.

Song Y, Zou L, Zhao J, *et al.* Whole brain volume and cortical thickness abnormalities in Wilson's disease: a clinical correlation study. *Brain Imaging Behav* 2020.

Tinaz S, Arora J, Nalamada K, *et al.* Structural and functional brain changes in hepatic and neurological Wilson disease. *Brain Imaging Behav* 2020.

Viveiros A, Beliveau V, Panzer M, *et al.* Neurodegeneration in Hepatic and Neurologic Wilson Disease. *Hepatology* 2020.

Hu S, Xu C, Dong T, *et al.* Structural and Functional Changes Are Related to Cognitive Status in Wilson's Disease. *Front Hum Neurosci* 2021;15:610947.

Dusek P, Lescinskij A, Ruzicka F, *et al.* Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease. *Radiology* 2021:202846.

Susceptibility-weighted imaging

Fritsch D, Reiss-Zimmermann M, Trampel R, *et al.* Seven-tesla magnetic resonance imaging in Wilson disease using quantitative susceptibility mapping for measurement of copper accumulation. *Invest Radiol* 2014;49(5):299-306.

Bai X, Wang G, Wu L, *et al.* Deep-gray nuclei susceptibility-weighted imaging filtered phase shift in patients with Wilson's disease. *Pediatr Res* 2014;75(3):436-42.

Zhou XX, Qin HL, Li XH, *et al.* Characterizing brain mineral deposition in patients with Wilson disease using susceptibility-weighted imaging. *Neurol India* 2014;62(4):362-6.

Yang J, Li X, Yang R, *et al.* Susceptibility-Weighted Imaging Manifestations in the Brain of Wilson's Disease Patients. *PLoS One* 2015;10(4):e0125100.

Dezortova M, Lescinskij A, Dusek P, *et al.* Multiparametric Quantitative Brain MRI in Neurological and Hepatic Forms of Wilson's Disease. *J Magn Reson Imaging* 2020;51(6):1829-1835.

Dusek P, Lescinskij A, Ruzicka F, *et al.* Associations of Brain Atrophy and Cerebral Iron Accumulation at MRI with Clinical Severity in Wilson Disease. *Radiology* 2021:202846.

Diffusion-weighted imaging

Jadav R, Saini J, Sinha S, *et al.* Diffusion tensor imaging (DTI) and its clinical correlates in drug naive Wilson's disease. *Metab Brain Dis* 2013;28(3):455-62.

Lawrence A, Saini J, Sinha S, *et al.* Improvement of Diffusion Tensor Imaging (DTI) Parameters with Decoppering Treatment in Wilson's Disease. *JIMD Rep* 2016;25:31-37.

Zhou XX, Li XH, Qin H, *et al.* Diffusion tensor imaging of the extracortical network in the brains of patients with Wilson disease. *J Neurol Sci* 2016;362:292-8.

Wang A, Wu H, Xu C, *et al.* Study on Lesion Assessment of Cerebello-Thalamo-Cortical Network in Wilson's Disease with Diffusion Tensor Imaging. *Neural Plast* 2017;2017:7323121.

Song YK, Li XB, Huang XL, *et al.* A study of neurite orientation dispersion and density imaging in wilson's disease. *J Magn Reson Imaging* 2018;48(2):423-430.

Dong T, Yang WM, Wu MC, *et al.* Microstructure changes in whiter matter relate to cognitive impairment in Wilson's disease. *Biosci Rep* 2019;39(3)

Hu S, Xu C, Dong T, *et al.* Structural and Functional Changes Are Related to Cognitive Status in Wilson's Disease. *Front Hum Neurosci* 2021;15:610947.

Table 3

Magnetic resonance spectroscopy

Van Den Heuvel AG, Van der Grond J, Van Rooij LG, *et al.* Differentiation between portal-systemic encephalopathy and neurodegenerative disorders in patients with Wilson disease: H-1 MR spectroscopy. *Radiology* 1997;203(2):539-43.

Kraft E, Trenkwalder C, Then Bergh F, *et al.* Magnetic resonance proton spectroscopy of the brain in Wilson's disease. *J Neurol* 1999;246(8):693-9.

Lucato LT, Otaduy MC, Barbosa ER, *et al.* Proton MR spectroscopy in Wilson disease: analysis of 36 cases. *AJNR Am J Neuroradiol* 2005;26(5):1066-71.

Tarnacka B, Szeszkowski W, Golebiowski M, *et al.* Metabolic changes in 37 newly diagnosed Wilson's disease patients assessed by magnetic resonance spectroscopy. *Parkinsonism Relat Disord* 2009;15(8):582-6.

Tarnacka B, Szeszkowski W, Golebiowski M, *et al.* MR spectroscopy in monitoring the treatment of Wilson's disease patients. *Mov Disord* 2008;23(11):1560-6.

Tarnacka B, Szeszkowski W, Buettner J, *et al.* Heterozygous carriers for Wilson's disease--magnetic spectroscopy changes in the brain. *Metab Brain Dis* 2009;24(3):463-8.

Pulai S, Biswas A, Roy A, *et al.* Clinical features, MRI brain, and MRS abnormalities of drug-naive neurologic Wilson's disease. *Neurol India* 2014;62(2):153-8.

Alkhalik Basha MA, Refaat R, Ahmed AF, *et al.* Brain magnetic resonance spectroscopy (MRS) as a diagnostic tool for detecting early neurological changes in children with Wilson's disease. *Eur J Radiol* 2019;111:41-46.

Single photon emission computed tomography

Barthel H, Sorger D, Kuhn HJ, *et al.* Differential alteration of the nigrostriatal dopaminergic system in Wilson's disease investigated with [¹²³I]ss-CIT and high-resolution SPET. *Eur J Nucl Med* 2001;28(11):1656-63.

Hermann W, Eggers B, Barthel H, *et al.* Correlation between automated writing movements and striatal dopaminergic innervation in patients with Wilson's disease. *J Neurol* 2002;249(8):1082-7.

Eggers B, Hermann W, Barthel H, *et al.* The degree of depression in Hamilton rating scale is correlated with the density of presynaptic serotonin transporters in 23 patients with Wilson's disease. *J Neurol* 2003;250(5):576-80.

Wang P, Hu P, Yue DC, *et al.* The clinical value of Tc-99m TRODAT-1 SPECT for evaluating disease severity in young patients with symptomatic and asymptomatic Wilson disease. *Clin Nucl Med* 2007;32(11):844-9.

Piga M, Murru A, Satta L, *et al.* Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease. *Eur J Nucl Med Mol Imaging* 2008;35(4):716-24.

Eo JS, Lee HY, Lee JS, *et al.* Automated Analysis of (¹²³I)-beta-CIT SPECT Images with Statistical Probabilistic Anatomical Mapping. *Nucl Med Mol Imaging* 2014;48(1):47-54.

Transcranial sonography

Walter U, Krolkowski K, Tarnacka B, *et al.* Sonographic detection of basal ganglia lesions in asymptomatic and symptomatic Wilson disease. *Neurology* 2005;64(10):1726-32.

Svetel M, Mijajlović M, Tomić A, *et al.* Transcranial sonography in Wilson's disease. *Parkinsonism Relat Disord* 2012;18(3):234-8.

Maskova J, Skoloudik D, Burgetova A, *et al.* Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases. *Parkinsonism Relat Disord* 2016;28:87-93.

Tribl GG, Trindade MC, Almeida KJ, *et al.* Quantitative transcranial sonography in Wilson's disease and healthy controls: Cut-off values and functional correlates. *J Neurol Sci* 2018;385:69-74.

Skowronska M, Litwin T, Kurkowska-Jastrzebska I, *et al.* Transcranial sonography changes in patients with Wilson's Disease during de-coppering therapy. *Neurol Neurochir Pol* 2020;54(2):185-192.

Skowronska M, Litwin T, Kurkowska-Jastrzebska I, *et al.* Transcranial sonography changes in heterozygotic carriers of the ATP7B gene. *Neurol Sci* 2020;41(9):2605-2612.

Skoloudik D, Maskova J, Dusek P, *et al.* Digitized Image Analysis of Insula Echogenicity Detected by TCS-MR Fusion Imaging in Wilson's and Early-Onset Parkinson's Diseases. *Ultrasound Med Biol* 2020;46(3):842-848.